Multimeric Biotherapeutics
Multimeric Biotherapeutics, Inc. is a biotechnology company based in San Diego, focused on developing immunotherapies and vaccines against infectious diseases and cancer. They are developing the FortiVac platform, which elicits strong CD8+ T cell responses for anti-viral and tumor immunotherapy. The company aims to address unmet medical needs in cancer and infectious disease vaccination, leveraging patented vaccine platform technology that enhances immune responses, particularly CD8+ T cell responses.
Industries
Nr. of Employees
small (1-50)
Multimeric Biotherapeutics
Products
Multimeric fusion-protein vaccine platform
A vaccine platform based on self-assembling multimeric fusion proteins that combine a TNF superfamily ligand extracellular domain, a multimerization scaffold, and antigen sequences to target dendritic cells and elicit high-level CD8+ T cell responses for applications in infectious disease and cancer.
FortiVac™
FortiVac is a nanostructured fusion protein vaccine platform that combines the CD40L extracellular domain with surfactant protein D to stimulate dendritic cells and generate high levels of CD8+ T cells for tumor eradication and viral infection treatment.
Multimeric fusion-protein vaccine platform
A vaccine platform based on self-assembling multimeric fusion proteins that combine a TNF superfamily ligand extracellular domain, a multimerization scaffold, and antigen sequences to target dendritic cells and elicit high-level CD8+ T cell responses for applications in infectious disease and cancer.
FortiVac™
FortiVac is a nanostructured fusion protein vaccine platform that combines the CD40L extracellular domain with surfactant protein D to stimulate dendritic cells and generate high levels of CD8+ T cells for tumor eradication and viral infection treatment.
Expertise Areas
- Vaccine platform development
- T-cell immunology focused on CD8+ responses
- Fusion protein engineering and multimerization scaffolds
- Preclinical murine efficacy and challenge models
Key Technologies
- Multimeric fusion proteins
- CD40 receptor-targeted antigen delivery
- Self-assembling protein scaffolds derived from surfactant protein D-like domains
- Adenoviral vector expression
News & Updates
Richard S. Kornbluth, MD, PhD, President & Chief Scientific Officer will present an overview of Multimeric’s new vaccine platform (FortiVacTM) that elicits very strong CD8+ T cell responses against the chosen antigen. The Company will present a poster and give a short talk about the technology.
The Company’s abstract is titled “CD40 ligand (CD40L) multi-trimer antigen fusion protein (FortiVacTM) as a vaccine design for high-level CD8+ T cell responses.” Richard S. Kornbluth will give a presentation and the company will present a poster.
The European Patent Office issued Patent No. EP 2 970 427 B1 for a composition comprising antigen linked to a TNF SuperFamily ligand, protecting FortiVac platform technology.
The U.S. Patent Office issued Patent No. 10/774/149 B2 for a composition comprising antigen linked to a TNF Superfamily ligand, supporting the development of FortiVac as a vaccine platform.
Richard S. Kornbluth, MD, PhD, President & Chief Scientific Officer will present an overview of Multimeric’s new vaccine platform (FortiVacTM) that elicits very strong CD8+ T cell responses against the chosen antigen. The Company will present a poster and give a short talk about the technology.
The Company’s abstract is titled “CD40 ligand (CD40L) multi-trimer antigen fusion protein (FortiVacTM) as a vaccine design for high-level CD8+ T cell responses.” Richard S. Kornbluth will give a presentation and the company will present a poster.
The European Patent Office issued Patent No. EP 2 970 427 B1 for a composition comprising antigen linked to a TNF SuperFamily ligand, protecting FortiVac platform technology.
The U.S. Patent Office issued Patent No. 10/774/149 B2 for a composition comprising antigen linked to a TNF Superfamily ligand, supporting the development of FortiVac as a vaccine platform.